1. Pink Sheet
  2. >>Market Access

The Real Test for Gardasil: Money, not Morals

 
• By Kate Rawson

The real test for Gardasil isn't FDA approval or the Advisory Committee on Immunization Practices' recommendation for universal vaccination. In the long run, Gardasil's commercial success will be depend more on the future of the Vaccines for Children Act--and how long the government wants to continue to sign blank checks for childhood vaccinations.

Merck & Co. Inc. ’s human papilloma virus vaccine Gardasil sailed through FDA’s Vaccines and Related Biological Products Advisory Committee during a May 18 review. Despite lingering questions about whether HPV causes cervical cancer—generally an undisputed scientific finding—the committee unanimously recommended FDA approval of the three-dose vaccine series in female patients 9 to 26 years of age.

Now all eyes are on the Centers for Disease Control & Prevention’s Advisory Committee on Immunization Practices’ final review of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

‘Prices Can Remain Contaminated Indefinitely’: Advanz Brushed Aside On UK Liothyronine Appeal

 
• By Dean Rudge

England’s Court of Appeal has upheld a Competition Appeal Tribunal’s 2023 finding that Advanz and its former owner Cinven abused their dominant position in the UK market for liothyronine tablets by charging prices that were many orders of magnitude higher than the benchmark for fair pricing.

New EU Filings

 
• By Neena Brizmohun

Linerixibat, GSK's treatment for cholestatic pruritus in patients with primary biliary cholangitis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 
• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.